• FDA Approves Avapritinib for Advanced Systemic Mastocytosis americanpharmaceuticalreview
    June 18, 2021
    The U.S. FDA approved avapritinib (Ayvakit™, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated ...
PharmaSources Customer Service